Oncologists worry that HHS's cutoff of mRNA research could lead to a broader hostile posture towards using mRNA and hamper cancer treatments.
The deal ratchets up Exact’s intense competition with Guardant, which received FDA approval last year for its own colon cancer liquid biopsy
Scientists call mRNA technology safe and effective, say Kennedy's "unscientific and misguided" decision will hamper research and pandemic response.
In studies reliant on global partners because of the small number of patients, NIH overseas funding cuts turn patients into collateral damage
